secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088234
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO
-------------------------------------------------------------------------

- Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.
- GAAP net income $1.5M (EPS $0.00) vs net loss $17.6M in Q2 2023; non-GAAP adj. net income $5.9M.
- Cash $306.7M; $50M share repurchase program approved but not commenced.
- Large PBM removed VASCEPA from exclusive coverage for Commercial national formularies effective July 1, 2024.
- CEO Aaron Berg appointed; China CVRR milestone $15M; new EU patent extending VAZKEPA exclusivity to 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/0000950170-24-088234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/amrn-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer